HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Group recommends targeting CER for priority populations

This article was originally published in The Tan Sheet

Executive Summary

Federal agencies should target comparative effectiveness research funds for studies involving racial and ethnic minorities, children, women, the elderly and people with multiple chronic conditions, the Brookings Institution's Engelberg Center for Health Care Reform says. The center's draft report recommends government organizations that support CER "allocate research funds to meritorious investigator-initiated proposals that are responsive to priority populations, and create targeted funding opportunities to fill gaps." The health care reform Congress enacted in March requires CER and gives oversight to a federal institute operating in a public/private partnership mode (1"The Tan Sheet" April 19, 2010). The draft notes research does not focus enough on conditions that affect priority populations, and priority populations typically are not recruited for trials. Another problem is the clinical trials infrastructure is not set up to allow for more participation from members of priority groups

You may also be interested in...



Comparative Effectiveness Could Take A Close Look At CAM - Sebelius

Comparative effectiveness research required under health care reform likely will be used to carefully test the value of complementary and alternative medicines rather than simply hold up those products as less-expensive alternatives to pharmaceuticals

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel